{"member_organisations": "none", "identification_number": "4263301811-33", "fields_of_interest": "General and Institutional Affairs, Economy, finance and the euro, Trade, Competition, Consumers, Customs, Business and Industry, Environment, Taxation, Justice and Fundamental Rights, Single market, Research and innovation, External Relations, Public Health", "head_office_address": "East 42nd Street, 235", "full_time_equivalent_fte": "2", "person_with_legal_responsibility": "Ian C. Read", "inter_groups": "", "financial_year_start_date": "01/01/2016", "grants": "", "head_office_country": "United States", "eu_initiatives": "EU Incentives review, Pediatric & Orphan Review, Brexit negotiations, GDPR implementation, AMR Joint Action, Vaccines Joint Action, HTA Joint Action,  Pharmaceuticals in the Environment,  FP9 and IMI-related work, key Trade negotiations such as CETA, Mexico, Japan, proposal on public country-by-country reporting (CBCR)", "organisation_name": "Pfizer Inc. (PFE)", "belgium_office_post_code": "1050", "number_of_persons_involved": "5", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "Boulevard de la Plaine 17", "subsection": "Companies & groups", "belgium_office_phone": "(+32)25546211", "number_of_ep_accredited_persons": "5", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "Brussels", "persons_accredited_for_access_to_european_parliament_premises": "AANDAHL#Eva Grut, CHIARELLO#ANDREA, CLAY#Matthew Thomas, FAID#Charles, GALBRAITH#Heike", "estimate_of_costs_absolute_amount": "", "registration_date": "18/12/2008", "website_address": "http://www.pfizer.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "New York", "membership": "In 2017 Pfizer was a member of: EFPIA, Vaccines Europe, EuropaBio, AESGP, Amcham EU, BusinessEurope, TABC &  AECA", "head_office_post_code": "NY 10017", "goals__remit": "At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.  We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.  Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.    Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  In 2016, Pfizer's full year revenue was $52.8 Billion, with approx. 8% invested in research and development.To learn more, please visit us at www.pfizer.com.", "industry_forums": "", "head_office_phone": "(+1)2127332323", "level_of_interest": "global", "relevant_communication": "None foreseen", "financial_year_end_date": "01/12/2016", "estimate_of_costs_as_a_range": "800000-899999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation", "person_in_charge_of_eu_relations": "Eva Grut-Aandahl", "customers": "", "belgium_office_post_box": "", "position": "Head of EU Office"}